LENZ Therapeutics, Inc. - Common Stock LENZ 深 沪
等待开盘 12-20 09:30:00 美东时间
18.00
+0.930
+5.45%
华盛通- 最 高18.47
- 今 开17.18
- 成交量 108.09万股
- 最 低 17.18
- 昨 收 17.07
- 总市值 5.07亿
- 52周最高 50.40
- 市盈率 静 --
- 换手率 3.84%
- 52周最低 15.70
- 委 比 -20.00%
- 总股本 2814.62万
- 历史最高 230.79
- 量 比 0.42
- 振 幅 7.56%
- 历史最低 3.92
- 每 手 1
- 风险率 6.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LENZ Therapeutics Acknowledges Adverse Event Reported To FDA; Says Patient Using VIZZ Experiences Retinal Tear, Cause Uncertain Due To Pre-Existing Risk Factors
LENZ Therapeutics, Inc. ("the Company") is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration's ("FDA") Adverse Event Reporting System ("FAERS") database describing a retinal tear
12-13 05:29
LENZ Therapeutics And Lotus Pharmaceutical Announces That Lotus Has Submitted A New Drug Application To South Korea's Ministry Of Food And Drug Safety For Vizz, Intended To Treat Presbyopia In Adults
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety
12-01 21:33
LENZ Therapeutics shares are trading lower. The company reported Q3 financial results.
LENZ Therapeutics shares are trading lower. The company reported Q3 financial r...
11-05 22:26
LENZ Therapeutics Q3 EPS $(0.59) Beats $(0.67) Estimate, Sales $12.500M Beat $6.828M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.67) by 11.54 percent. This is a 55.26 percent decrease over losses of $(0.38) per share from
11-05 21:06
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Artelo Biosciences Appoints Mark Spring CFO, Effective Nov. 1
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
10-27 20:01
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Raymond James Reiterates Outperform on LENZ Therapeutics, Raises Price Target to $50
Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target from $40 to $50.
10-21 01:18
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Piper Sandler Maintains Overweight on LENZ Therapeutics, Raises Price Target to $67
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target from $51 to $67.
10-10 20:52
